

Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis

William J. Burman, Stefan Goldberg, John L. Johnson, Grace Muzanye, Melissa Engle, Ann W. Mosher, Shurjeel Choudhri, Charles L. Daley, Sonal S. Munsiff, Zhen Zhao, Andrew Vernon, Richard E. Chaisson, and the Tuberculosis Trials Consortium

Denver Public Health and the Department of Medicine, University of Colorado Health Sciences; National Jewish Medical and Research Center, Denver, Colorado; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia; Department of Medicine, Division of Infectious Diseases, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio; Uganda–Case Western Reserve University Research Collaboration, Kampala, Uganda; South Texas Veterans Health Care System, San Antonio, Texas; Duke University Medical Center, Durham, North Carolina; Bayer, Inc., West Haven, Connecticut; New York City Department of Health and Mental Hygiene, New York, New York; and Johns Hopkins University Center for TB Research, Baltimore, Maryland

Rationale: Moxifloxacin has promising preclinical activity against *Mycobacterium tuberculosis*, but has not been evaluated in multidrug treatment of tuberculosis in humans.

Objective: To compare the impact of moxifloxacin versus ethambutol, both in combination with isoniazid, rifampin, and pyrazinamide, on sputum culture conversion at 2 mo as a measure of the potential sterilizing activity of alternate induction regimens.

Methods: Adults with smear-positive pulmonary tuberculosis were randomized in a factorial design to receive moxifloxacin (400 mg) versus ethambutol given 5 d/wk versus 3 d/wk (after 2 wk of daily therapy). All doses were directly observed.

Measurements: The primary endpoint was sputum culture status at 2 mo of treatment.

Results: Of 336 patients enrolled, 277 (82%) were eligible for the efficacy analysis, 186 (67%) were male, 175 (63%) were enrolled at African sites, 206 (74%) had cavitation on chest radiograph, and 60 (22%) had HIV infection. Two-month cultures were negative in 71% of patients (99 of 139) treated with moxifloxacin versus 71% (98 of 138) treated with ethambutol ($p = 0.97$). Patients receiving moxifloxacin, however, more often had negative cultures after 4 wk of treatment. Patients treated with moxifloxacin more often reported nausea (22 vs. 9%, $p = 0.002$), but similar proportions completed study treatment (88 vs. 89%). Dosing frequency had little effect on 2-mo culture status or tolerability of therapy.

Conclusions: The addition of moxifloxacin to isoniazid, rifampin, and pyrazinamide did not affect 2-mo sputum culture status but did show increased activity at earlier time points.

Keywords: efficacy; moxifloxacin; randomized trial; toxicity; tuberculosis

New agents are needed for the treatment of drug-susceptible and drug-resistant tuberculosis. Treatment of drug-susceptible tuberculosis is very effective, but the need for 6 mo of therapy poses challenges to patients and tuberculosis control programs. A major goal of tuberculosis research is to identify shorter treatment regimens. The newer fluoroquinolone antibiotics, moxifloxacin and gatifloxacin, have potent activity *in vitro* and in animal models of tuberculosis treatment (1–3). In a murine model of tuberculosis treatment, moxifloxacin adds to the sterilizing activity of multidrug therapy with isoniazid, rifampin, and

pyrazinamide (4). In addition, moxifloxacin has been shown to have potent activity in the first few days of tuberculosis treatment (early bactericidal activity) as monotherapy (5–7) or with isoniazid (8). The activity and tolerability, however, of moxifloxacin in multidrug treatment of human tuberculosis have not been evaluated previously.

The definitive measure of the sterilizing activity of a multidrug tuberculosis treatment regimen is its ability to prevent treatment failure and relapse. Trials using treatment failure plus relapse as endpoints, however, require large sample sizes (> 1,000 patients) and follow-up for 1 to 2 yr after completion of therapy. Previous trials have shown a strong correlation between the rate of relapse and the ability of a regimen to convert sputum cultures to negative after 2 mo of therapy (9–11). Two-month sputum culture conversion is an appropriate surrogate marker for the initial evaluation of a new drug regimen for tuberculosis treatment.

Intermittent dosing fosters the use of directly observed therapy. An important part of the assessment of a new drug for tuberculosis is an evaluation of its suitability for intermittent dosing. In a factorial design, the Tuberculosis Trials Consortium evaluated the activity and tolerability of moxifloxacin substituted for ethambutol and the effect of 5 d/wk versus 3 d/wk dosing during the first 8 wk of tuberculosis therapy. We reasoned that if moxifloxacin significantly improved 2-mo sputum culture conversion rates, a larger phase 3 trial of moxifloxacin to shorten therapy would be justified. Preliminary results of this study were reported in a presentation at the 2005 Interscience Conference on Antimicrobial Agents and Chemotherapy (12).

METHODS

Patients 18 yr or older with suspected pulmonary tuberculosis and acid-fast bacilli in an expectorated sputum sample were eligible for enrollment. Patients were excluded if they had received more than 7 d of a fluoroquinolone antibiotic or tuberculosis treatment within the previous 6 mo; were pregnant or breast-feeding; or if the initial sputum cultures were negative for *Mycobacterium tuberculosis* or grew a strain resistant to rifampin, fluoroquinolones, or pyrazinamide (patients whose isolates were resistant to isoniazid were included) (13). All patients underwent HIV testing. A complete listing of inclusion and exclusion criteria is available in the online supplement. The study was approved by the Centers for Disease Control and Prevention (CDC) and local institutional review boards, and patients gave informed consent.

Patients were randomized in a factorial design to two interventions: moxifloxacin (400 mg) versus ethambutol, and treatment 5 d/wk versus thrice weekly, following an initial 2 wk of daily therapy. Randomization was stratified by continent of enrollment and presence of pulmonary cavitation. Patients received moxifloxacin or matching placebo and ethambutol or matching placebo. Isoniazid, rifampin, and pyrazinamide were obtained from licensed suppliers in the United States or Europe (see Table 1 for doses). All doses were supervised. Completion of study therapy was defined as ingestion of 40 doses (5 d/wk treatment) or

(Received in original form March 11, 2006; accepted in final form May 1, 2006)

Supported by the U.S. Centers for Disease Control and Prevention.

Correspondence and requests for reprints should be addressed to William J. Burman, M.D., 605 Bannock Street, Denver, CO 80204. E-mail: bburman@dhha.org

This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org

Am J Respir Crit Care Med Vol 174, pp 331–338, 2006

Originally Published in Press as DOI: 10.1164/rccm.200603-3600C on May 4, 2006
Internet address: www.atsjournals.org

TABLE 1. DOSES OF STUDY MEDICATIONS DURING THE INTENSIVE PHASE

| Drug | Dose for Daily Therapy | Dose for Thrice-Weekly Therapy |
|--------------|------------------------|--------------------------------|
| Moxifloxacin | 400 mg | 400 mg |
| Rifampin | | |
| ≤ 45 kg | 450 mg | 450 mg |
| > 45 kg | 600 mg | 600 mg |
| Isoniazid | 300 mg | 15 mg/kg, max. dose 900 mg |
| Pyrazinamide | | |
| 40–55 kg | 1,000 mg | 1,500 mg |
| 56–75 kg | 1,500 mg | 2,500 mg |
| 76–90 kg | 2,000 mg | 3,000 mg* |
| Ethambutol | | |
| 40–55 kg | 800 mg | 1,200 mg |
| 56–75 kg | 1,200 mg | 2,000 mg |
| 76–90 kg | 1,600 mg | 2,400 mg* |

* Maximum dose, regardless of weight.

28 doses (thrice-weekly therapy). After completion of the first 2 mo of treatment, patients completed tuberculosis treatment with a recommended regimen (14).

Sputum cultures were performed at local laboratories that were required to use both broth and solid culture media. *M. tuberculosis*

isolates underwent confirmatory drug-susceptibility testing at the CDC using the proportion method (15). Fluoroquinolone resistance was defined as growth in the presence of 2 µg/ml of ciprofloxacin (16).

Data Analysis

The study was designed to detect a difference in sputum culture conversion that has been associated with the ability to shorten treatment. The addition of pyrazinamide, an intervention that allowed treatment to be shortened by 3 mo, increased 2-mo culture conversion rates by an average of 13% (17–20). To detect this difference using a one-sided test at the 0.05 level and 80% power requires 125 patients per group for the two primary comparisons (e.g., moxifloxacin vs. ethambutol). We increased this by 30% to compensate for patient drop-out, and missing or overgrown cultures.

The primary efficacy endpoint was the proportion of patients with negative cultures after 2 mo of treatment. Following the practice of the British Medical Research Council, we excluded (1) patients who took nonstudy therapy or required more than 70 d to complete the intensive phase, (2) patients who died during the intensive phase of therapy, and (3) patients whose sputum cultures were overgrown with bacteria or yeast. Patients who received at least one dose of study drug were included in the safety analysis.

We analyzed data using SAS (version 8.2; SAS Institute, Inc., Cary, NC) and EpiInfo (version 6.04; CDC, Atlanta, GA) software packages.




Figure 1. Enrollment and disposition of patients.

TABLE 2. CHARACTERISTICS OF PATIENTS INCLUDED IN THE EFFICACY ANALYSIS (n = 277)

| Characteristic | Moxifloxacin | | Ethambutol | |
|--|------------------|------------------|------------------|-----------------|
| | 5 d/wk (n = 68) | 3 d/wk (n = 71) | 5 d/wk (n = 68) | 3 d/wk (n = 70) |
| Median age, yr (IQR) | 30 (23–40) | 32 (27–44) | 30 (23–39) | 32 (25–42) |
| Male, n (%) | 43 (63) | 55 (78) | 41 (60) | 47 (67) |
| Continent of enrollment, n (%) | | | | |
| Africa | 43 (63) | 44 (62) | 42 (62) | 46 (66) |
| North America | 25 (37) | 27 (38) | 26 (38) | 24 (34) |
| Race or ethnicity, n (%) | | | | |
| Non-Hispanic black | 55 (81) | 50 (70) | 52 (77) | 47 (67) |
| Non-Hispanic white | 4 (6) | 3 (4) | 1 (2) | 3 (4) |
| Hispanic | 4 (6) | 12 (17) | 8 (12) | 15 (22) |
| Asian and Pacific Islander | 4 (6) | 5 (7) | 6 (9) | 4 (6) |
| Other | 1 (1) | 1 (1) | 1 (2) | 1 (1) |
| Sociologic features (within the past year), n (%) | | | | |
| Less than high school education | 46 (68) | 45 (63) | 48 (71) | 54 (77) |
| Homeless | 4 (6) | 2 (3) | 4 (6) | 1 (1) |
| Injection drug use | 2 (3) | 0 (0) | 1 (2) | 0 (0) |
| Excess alcohol use | 7 (10) | 9 (13) | 3 (4) | 5 (7) |
| Clinical features | | | | |
| Median body weight, kg (IQR) | 56 (50–62) | 56 (51–62) | 54 (48–61) | 53 (48–61) |
| Median body mass index (IQR) | 20 (18–22) | 20 (19–22) | 20 (18–22) | 19 (18–22) |
| Cavitation on chest radiograph, n (%) | 50 (74) | 52 (73) | 51 (75) | 53 (76) |
| Bilateral disease on chest radiograph, n (%) | 38 (57) | 47 (66) | 41 (60) | 43 (62) |
| Laboratory features | | | | |
| Isoniazid-resistant isolate, n (%) | 10 (15) | 5 (7) | 5 (7) | 5 (7) |
| Median hemoglobin, g/dl (IQR) | 11.6 (10.4–13.2) | 11.8 (10.5–13.3) | 11.5 (10.1–13.1) | 11.6 (9.4–13.1) |
| HIV infection, n (%) | 15 (22) | 15 (21) | 16 (24) | 14 (20) |
| Median CD4 lymphocyte count, cells/mm ³ (IQR) | 136 (85–279) | 234 (106–446) | 254 (151–357) | 176 (108–314) |
| Median plasma HIV RNA level, log ₁₀ copies/ml (IQR) | 4.9 (4.7–5.1) | 5 (4.8–5.9) | 5 (4.1–5.4) | 5 (4.8–5.2) |
| Tuberculosis treatment before enrollment | | | | |
| Any treatment within 7 d, n (%) | 29 (43) | 25 (35) | 30 (44) | 28 (40) |
| Median number of days of treatment (IQR)* | 5 (3–6) | 4 (3–5) | 5 (3–6) | 5 (3–6) |

Definition of abbreviation: IQR = interquartile range.

* Among patients with any treatment before enrollment.

We evaluated factors associated with a negative 2-mo culture using the χ^2 test. Multivariate logistic regression was performed, using backward elimination, considering the same factors. Treatment regimen and all variables with multivariate $p < 0.05$ are shown in a final model.

More details on methods can be found in the online supplement.

RESULTS

A total of 336 patients with suspected smear-positive pulmonary tuberculosis were enrolled from July 2003 through March 2005. Four patients did not receive study drug, so 332 patients are included in the safety analysis (Figure 1). Twenty patients were found to be ineligible after enrollment (negative culture, 5; growth of a nontuberculous mycobacterium, 4; resistance to rifampin, fluoroquinolones, or pyrazinamide, 11). An additional 35 patients could not be assessed for 2-mo culture status (stopped assigned therapy because of toxicity, 14; nonadherence, 5; contaminated or lost cultures, 3; inappropriately timed cultures, 4; withdrew consent, 3; pregnancy, 1; death, 1; moved, 4). A total of 277 patients (82% of those enrolled) were included in the efficacy analysis, with similar proportions from each of the four study arms being included in the efficacy analysis.

Table 2 shows demographic and clinical characteristics of the 277 patients included in the efficacy analysis. The median age was 31 yr (interquartile range, 24–40 yr); 186 (67%) were male; 175 (63%) were enrolled at African sites; 206 (74%) had cavitation on chest radiograph; and 60 (22%) had HIV infection. Patients with HIV infection had a median CD4 lymphocyte count of 196 cells/mm³ (interquartile range, 112–319) and median plasma HIV RNA level of 5 (4.5–5.3) log₁₀ copies/ml. A higher

proportion of those receiving thrice-weekly moxifloxacin were male; otherwise, the study arms were well balanced for baseline characteristics. Of the 277 patients in the efficacy analysis, 274 (99%) had sputum specimens obtained at the 2-mo time point.

There was no significant interaction between the two interventions evaluated (moxifloxacin vs. ethambutol, treatment 5 d/wk vs. 3 d/wk, $p = 0.27$), so the analysis proceeded using the factorial design. Two-month cultures were negative in 99 (71%) of 139 patients treated with moxifloxacin versus 98 (71%) of 138 patients treated with ethambutol ($p = 0.97$; Table 3). Two-month culture status was also similar among patients who received therapy 5 d/wk versus 3 d/wk (100 [74%] of 136 vs. 97 [69%] of 141 patients, $p = 0.39$). We performed two *post hoc* analyses of the effect of treatment assignment (*see* online supplement for additional

TABLE 3. TWO-MONTH SPUTUM CULTURE CONVERSION, BY STUDY ARM AND THE FACTORIAL DESIGN

| Treatment | Treatment Frequency | | |
|--------------|--------------------------|--------------------------|-----------------------|
| | 5 d/wk | 3 d/wk | Combined [‡] |
| Moxifloxacin | 48/68 (71%) [†] | 51/71 (72%) [†] | 99/139 (71%) |
| Ethambutol | 52/68 (76%) [†] | 46/70 (66%) [†] | 98/138 (71%) |
| Combined* | 100/136 (74%) | 97/141 (69%) | |

[†] Overall, $p = 0.52$.

[‡] Comparing drug treatment arms, $p = 0.97$.

* Comparing treatment frequency arms, $p = 0.39$.




Figure 2. Proportion of sputum cultures negative at Weeks 2, 4, 6, and 8 of treatment by study drug (A) and dosing frequency (B).

details). First, in an analysis of all patients with a 2-mo culture result (whether or not they remained on or completed their assigned regimen), there was no difference between moxifloxacin and ethambutol (cultures were negative in 113 [72%] of 156 and 109 [71%] of 153 patients, respectively). Second, 2-mo culture status was not affected by treatment assignment among the 252 patients having isoniazid-susceptible isolates (cultures were negative in 88 [71%] of 124 and 91 [71%] of 128 patients receiving moxifloxacin and ethambutol, respectively).

A secondary endpoint of the trial was sputum culture status at time points earlier in therapy. Sputum cultures were more likely to be negative among patients who received moxifloxacin both at Week 4 (37% [62 of 167] vs. 26% [43 of 165], $p = 0.05$) and at Week 6 (54% [90 of 167] vs. 42% [69 of 165], $p = 0.06$; Figure 2). Dosing frequency did not have a significant effect on sputum culture results at any of the time points assessed.

Pulmonary cavitation was associated with markedly lower 2-mo culture conversion (66% [137 of 206] vs. 84% [60 of 71] among those without cavitation, $p < 0.005$; Table 4). As anticipated in designing enrollment stratification by both region and cavitation, more African patients had baseline pulmonary cavitation (142 [81%] of 175) than did non-African patients (64 [63%] of 102, $p = 0.0007$). Enrollment at an African site was also associated with markedly lower culture conversion (63% [110 of 175] vs. 85% [87 of 102] of patients enrolled at North American sites, $p = 0.0001$). Notably, among evaluable patients at the two African sites in our study, 2-mo culture status was somewhat lower in patients enrolled in Kampala (61% [90 of 147]) compared with patients enrolled in Durban (71% [20 of 28], $p = 0.31$). Because randomization was stratified both by cavitation

and continent of enrollment, adjustment for these factors did not affect the analyses of moxifloxacin versus ethambutol and dosing frequency. HIV serostatus was not associated with culture conversion at 2 mo (43 [72%] of 60 HIV-positive patients converted cultures vs. 153 [71%] of 216 HIV-negative patients). In multivariate analysis, pulmonary cavitation, enrollment at an African site, and age greater than 31 yr (the median value) were significantly associated with lower 2-mo sputum culture conversion (Table 4).

Tolerability and Safety

Similar proportions of patients randomized to moxifloxacin and ethambutol completed the assigned regimen (88% [145 of 165] and 89% [148 of 167], respectively; $p = 0.83$). Rates of serious adverse events also were similar, and most serious adverse events were hospitalizations thought to be unrelated to the study treatment (Table 5). The one death during the first 2 mo of treatment was thought to be caused by pulmonary embolism, unrelated to tuberculosis therapy. Patients who received moxifloxacin more often reported nausea (21.6 vs. 9.1%, $p = 0.002$), but this symptom seldom necessitated temporary or permanent discontinuation of study therapy (Table 5). Joint pain was somewhat more frequently reported by patients on moxifloxacin (34% [57 of 167] vs. 27% [44 of 165], $p = 0.15$), but no cases of tendonopathy or arthritis were recognized. Although visual changes were reported in all study groups, no cases of retinitis or optic neuritis were diagnosed.

There was no evidence of differential laboratory toxicity by study arm. Maximum values for hepatic and renal function tests and minimum values for hematology tests through the first month after the last study dose were similar between study arms, both by study drug and by treatment schedule (see the online supplement). Furthermore, no differences in adverse event rates or in symptoms were found between study arms during the first month after the last study dose (see the online supplement).

DISCUSSION

Substitution of moxifloxacin for ethambutol did not have an effect on 2-mo sputum culture status but did result in a higher frequency of negative cultures at earlier time points among patients with smear-positive pulmonary tuberculosis. These results suggest that moxifloxacin has sterilizing activity, but insufficient activity when used in the manner evaluated in this trial (i.e., added to isoniazid, rifampin, and pyrazinamide) to support treatment shortening based on the surrogate marker of 2-mo culture conversion. Although associated with more nausea, moxifloxacin was generally well tolerated. Compared with ethambutol as a fourth drug, similar proportions of patients completed their assigned study therapy. The second part of the factorial design evaluated a modest difference in dosing frequency, 5 d/wk compared with 3 d/wk (after 2 wk of daily therapy). As in previous studies of dosing frequency, this difference (40 vs. 28 doses) had little effect on activity and tolerability.

Investigators in Chennai sparked interest in the possible use of fluoroquinolones to shorten the treatment of drug-susceptible tuberculosis. Despite the lack of an appropriate control group, they reported very high 2-mo culture conversion rates (> 90% for all arms of the study) when ofloxacin was added to regimens including isoniazid, rifampin, and pyrazinamide (21). Our results are similar to those of a previous trial evaluating the addition of levofloxacin to standard four-drug therapy for HIV-related tuberculosis. Levofloxacin did not increase 2-mo culture conversion but was associated with a somewhat higher prevalence of negative cultures at earlier time points (22). The results of this and previous controlled trials (22, 23) are consistent in showing that the addition of a fluoroquinolone to current standard therapy

TABLE 4. FACTORS ASSOCIATED WITH 2-mo SPUTUM CULTURE STATUS (n = 277)

| Factor | 2-mo Culture Status, Number with Negative Cultures/Total (%) | Unadjusted OR (95% CI) | p Value | Adjusted OR (95% CI) [†] | p Value |
|--|--|------------------------|---------|-----------------------------------|----------|
| Age, yr | | | | | |
| > 31 (median) | 89/134 (66) | 0.6 (0.4–1.1) | 0.10 | 0.4 (0.2–0.8) | 0.003 |
| ≤ 31 | 108/143 (76) | | | | |
| Sex | | | | | |
| Female | 63/91 (69) | 0.9 (0.5–1.5) | 0.63 | | |
| Male | 134/186 (72) | | | | |
| Continent of enrollment | | | | | |
| Africa | 110/175 (63) | 0.3 (0.2–0.6) | 0.0001 | 0.3 (0.1–0.5) | < 0.0001 |
| North America | 87/102 (85) | | | | |
| Race or ethnicity | | | | | |
| Black, non-Hispanic | 134/204 (66) | 0.3 (0.2–0.6) | 0.001 | | |
| Other | 63/73 (86) | | | | |
| Body mass index | | | | | |
| > 19.74 (median) | 101/138 (73) | 1.2 (0.7–2.1) | 0.45 | | |
| ≤ 19.74 | 96/139 (69) | | | | |
| Hemoglobin | | | | | |
| > 11.6 g/dl (median) | 104/137 (76) | 1.6 (0.9–2.7) | 0.08 | | |
| ≤ 11.6 g/dl | 93/140 (66) | | | | |
| HIV status | | | | | |
| HIV-infected | 43/60 (72) | 1 (0.6–2) | 0.90 | | |
| HIV-uninfected | 153/216 (71) | | | | |
| Pulmonary cavitation | | | | | |
| Present | 137/206 (66) | 0.4 (0.2–0.7) | 0.005 | 0.4 (0.2–0.9) | 0.03 |
| Absent | 60/71 (84) | | | | |
| Extent of chest radiographic abnormalities | | | | | |
| Bilateral | 110/169 (65) | 0.5 (0.3–0.8) | 0.008 | | |
| Unilateral | 85/106 (80) | | | | |
| Pre-enrollment tuberculosis treatment* | | | | | |
| Any | 89/112 (79) | 2 (1.2–3.6) | 0.01 | | |
| None | 108/165 (65) | | | | |
| Isoniazid-resistant isolate at baseline | | | | | |
| Present | 18/25 (72) | 1 (0.4–2.6) | 0.92 | | |
| Absent | 179/252 (71) | | | | |
| Rifampin dose, mg/kg | | | | | |
| > 11.00 mg/kg (median) | 92/136 (68) | 0.7 (0.4–1.2) | 0.21 | | |
| ≤ 11.00 mg/kg | 105/141 (74) | | | | |
| Study drug | | | | | |
| Moxifloxacin | 99/139 (71) | 1 (0.6–1.7) | 0.97 | 1 (0.6–1.7) | 0.87 |
| Ethambutol | 98/138 (71) | | | | |
| Dosing frequency | | | | | |
| 5 d/wk | 100/136 (74) | 1.26 (0.75–2.12) | 0.39 | | |
| 3 d/wk | 97/141 (69) | | | | |

Definition of abbreviations: CI = confidence interval; OR = odds ratio.

* Tuberculosis treatment during the 7 d before enrollment.

[†] Multivariate logistic regression was performed, using backward elimination, considering all the factors in the table. Treatment regimen and all variables with multivariate $p < 0.05$ are shown in the adjusted model.

has some sterilizing activity (negative cultures at earlier time points), but does not have a significant effect on the 2-mo sputum culture. Earlier differences in sputum conversion might be important for treatment shortening, but data in support of this are currently lacking.

Recent studies suggest that the activity of moxifloxacin may be dependent on the drugs with which it is used. In a murine model of tuberculosis treatment, the replacement of isoniazid by moxifloxacin was much more potent than the addition of moxifloxacin to isoniazid, rifampin, and pyrazinamide (2.5 log₁₀ greater killing at the 2-mo time point) (4). Furthermore, when moxifloxacin was used in place of isoniazid, all animals were culture negative by 3 mo of treatment, and treatment could be shortened to 4 mo (24). Despite the failure of our study to show enhanced 2-mo culture conversion, fluoroquinolone antibiotics may still allow significant shortening of the treatment of drug-susceptible tuberculosis.

Sputum culture conversion was substantially lower among patients enrolled in the two African sites than among patients enrolled at North American sites. In addition, the 2-mo culture conversion rates at African sites in our study were lower than those in previous studies in east Africa (17–19), perhaps in part because of the higher sensitivity of using both broth and solid culture media in the present study (whereas earlier studies used solid media alone). Patients enrolled at African sites more often had pulmonary cavitation and less often had received any tuberculosis treatment before study enrollment, both of which were associated with lower sputum culture conversion. Enrollment at an African site, however, retained an association with 2-mo culture status after adjustment for these two factors. It is possible that some of the difference between African and North American patients was caused by a greater overall severity of illness that was not reflected in the relatively crude measure of the presence or absence of pulmonary cavitation. Other possible

TABLE 5. ADVERSE EVENTS AND REPORTED SYMPTOMS DURING THE FIRST 2 mo OF TREATMENT, BY TREATMENT ARM

| Adverse Event | Moxifloxacin (n = 167) | Ethambutol (n = 165) | p Value | Relative Risk (95% CI) |
|--|---------------------------|-------------------------|---------|---------------------------|
| Death | 1 (0.6) | 0 (0) | 1.0 | 3 (0.1–72.2) |
| Hospitalization | 8 (5) | 6 (4) | 1.0 | 0.9 (0.4–2.3) |
| Any serious adverse event* | 10 (6) | 8 (5) | 0.81 | 1.2 (0.5–3.1) |
| Serious adverse event attributed to study therapy† | 0 (0) | 1 (0.6) | 0.50 | 0.3 (0.01–8) |
| Study drug temporarily or permanently discontinued | 17 (10) | 18 (10) | 0.86 | 0.9 (0.5–1.8) |
| Any grade 3 or 4 toxicity | 31 (19) | 19 (12) | 0.091 | 1.6 (0.95–2.7) |
| Hepatotoxicity | 6 (4) | 7 (4) | 0.79 | 0.9 (0.3–2.5) |
| Nausea or vomiting | 4 (2) | 0 (0) | 0.12 | 8.9 (0.5–164) |
| Vision change | 10 (6) | 9 (6) | 1.00 | 1.1 (0.5–2.6) |
| Diarrhea | 3 (2) | 0 (0) | 0.25 | 6.9 (0.4–133) |
| Selected symptoms (any grade) | | | | |
| Nausea | 36 (22) | 15 (9) | 0.002 | 2.4 (1.4–4.2) |
| Vomiting | 20 (12) | 15 (9) | 0.48 | 1.3 (0.7–2.5) |
| Diarrhea | 12 (7) | 6 (4) | 0.23 | 2 (0.8–5.1) |
| Fever | 29 (17) | 20 (12) | 0.22 | 1.4 (0.9–2.4) |
| Dizziness | 24 (14) | 15 (9) | 0.17 | 1.6 (0.9–2.9) |
| Joint pain | 57 (34) | 44 (27) | 0.15 | 1.3 (0.9–1.8) |

Definition of abbreviation: CI = confidence interval.

* Death, hospitalization, disabling event, grade 4 adverse event.

† Definite, probable, or possible relationship to study drug, per local investigator.

explanations (drug malabsorption, inadequate drug formulation) are being investigated, although all patients were treated with drugs approved by national regulatory agencies in the United States or Europe. Although not fully explained at this time, the difference between bacteriologic response rates of African and North American patients in our trial clearly demonstrates the need to evaluate new treatments for tuberculosis in a diverse patient population.

In this and previous studies, fluoroquinolone antibiotics were well tolerated when given for 2 mo or longer. Our trial design compared moxifloxacin with ethambutol, the best tolerated of the first-line antituberculosis drugs. Nausea, a side effect previously associated with the fluoroquinolones, was more common among patients treated with moxifloxacin, but seldom resulted in drug discontinuation. Similar to the previous trial of the addition of levofloxacin (22), there was no association between moxifloxacin and more serious side effects. These data add to the growing and favorable experience with prolonged use of fluoroquinolones in the treatment of multidrug resistant tuberculosis (25, 26) and *Chlamydia pneumoniae* (27). All of these studies suggest that moxifloxacin has an acceptable safety profile that allows it to be used in studies of treatment of drug-susceptible tuberculosis (28, 29). The recent report of the association between dysglycemia and the use of gatifloxacin is a reminder of the eventual need for larger phase 3 studies to evaluate more fully the safety of fluoroquinolones in tuberculosis treatment (30).

Intermittent dosing fosters directly observed therapy by decreasing the number of encounters necessary to ensure treatment compliance. Intermittent dosing during the intensive phase of therapy using current standard therapy may increase the risk of relapse, however, among patients with cavitary pulmonary tuberculosis (31). Several lines of evidence suggest that moxifloxacin may be effective when dosed intermittently. The serum half-life of moxifloxacin is approximately 12 h (32), substantially longer than that of isoniazid, rifampin, and streptomycin, all of which have good activity when dosed intermittently (33). Furthermore, once-weekly moxifloxacin had favorable activity in the continuation phase of treatment in a murine model (34). Our results are similar to those of previous randomized trials of daily versus thrice-weekly therapy during the intensive phase:

slightly lower rates of sputum culture conversion with intermittent therapy (not statistically significant in any previous trial) and similar tolerability (17–20). The lack of a significant difference in 2-mo culture status in our study may also be caused by the modest difference in dosing frequency evaluated; “daily therapy” was defined as dosing 5 d/wk. The role of intermittent therapy during the intensive phase requires additional research.

Our study has several limitations. We used 2-mo culture status as a surrogate marker for sterilizing activity and did not monitor patients for relapse, the definitive marker of sterilizing activity. Studies powered to compare relapse require large sample sizes, however, and it is very difficult to evaluate all new drugs, doses, and drug combinations using studies comparing relapse rates. There are uncertainties about the use of 2-mo culture status as a surrogate marker and a need for further research on surrogate markers of drug activity in tuberculosis treatment. Two-month culture status does correlate with sterilizing potential, however, and its use as a primary end point allows comparisons of regimens using sample sizes that are feasible for early drug development efforts. We evaluated only one dosage of one of the potent fluoroquinolone antibiotics. In a study of early bactericidal activity, moxifloxacin, gatifloxacin, and high-dose levofloxacin had comparable early bactericidal activity (7). Similarly, we only evaluated one way of using moxifloxacin (substitution for ethambutol), and the decreased activity of regimens including both moxifloxacin and isoniazid in a murine model of rifamycin-containing tuberculosis treatment (4, 35) suggest that we may not have used moxifloxacin in an optimal regimen in our trial. This trial was powered to detect a relatively large effect of the addition of moxifloxacin (an increase of 13% in culture negativity at 2 mo) because our interest is in identifying more potent induction phase regimens that would allow treatment shortening. Moxifloxacin may have a smaller effect on 2-mo culture status that was not detected in this study. Finally, we did not use a standard method for mycobacterial culture at all sites, but because randomization was stratified by continent of enrollment, this should not have confounded the comparison of moxifloxacin versus ethambutol.

CONCLUSIONS

We have shown that the addition of moxifloxacin to isoniazid, rifampin, and pyrazinamide has sterilizing activity, but is unlikely to allow for significant shortening of tuberculosis treatment. The activity and tolerability of moxifloxacin in this study support additional evaluation of moxifloxacin in the treatment of drug-susceptible tuberculosis.

Conflict of Interest Statement: W.J.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.L.J. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.W.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.C. is an employee of Bayer Healthcare: Pharmaceutical Division. C.L.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.S.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.V. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.E.C. was paid \$1,200 by Bayer to chair an Independent Data Safety Monitoring Board for a study of interleukin-2 for treatment of HIV infection in 2004 and 2005. He received a donation of moxifloxacin and placebo tablets from Bayer for a clinical trial of moxifloxacin to treat tuberculosis, which is funded by the U.S. Food and Drug Administration. Bayer holds the patent for moxifloxacin, one of the study drugs used in this trial.

Acknowledgment: The authors thank the many patients who contributed to the success of this trial. They are grateful to Drs. Kenneth Castro, Michael Iademarco, Rick O'Brien, and M. Elsa Villarino for continued support within the CDC, and local TB program staff who assisted in the clinical management of the participants. Philip Spradling, M.D., contributed to the planning and initial implementation of this study, and his efforts were exemplary and facilitated the successful conclusion of this trial. Bayer Pharmaceuticals donated the moxifloxacin and moxifloxacin placebo tablets.

Participating clinical sites (principal investigators and study coordinators, with numbers of patients enrolled in parentheses) were as follows: *Uganda-Case Western Reserve University Research Collaboration* (154)—John L. Johnson, M.D., Roy D. Mugerwa, M.B., Ch.B., M.Med., Grace Muzany, M.B., Ch.B., Sandra Rwambuya, M.P.H., Susan Kayes, B.S., and Yusuf Mulumba; *University of KwaZulu Natal-Harlem Hospital Research Collaboration* (36)—Wafaa El-Sadr, M.D., Nesri Padayatchi, M.D., Sheila Bamber, M.D., Surie T. Christop Chinappa, M.D., Yael Hirsch-Moverman, Ph.D., Vikesh Naidoo, and Nelisiwe Mnguni; *University of North Texas Health Science Center* (19)—Stephen Weis, D.O., Barbara King, R.N., Lee Turk, R.N., Gloria Stevenson, Joseph Helal, R.Ph., and Norma Shafer, L.V.N.; *Michael DeBakey Veterans Affairs Medical Center* (17)—Richard Hamill, M.D., Christopher Lahart, M.D., Elizabeth Guy, M.D., Terry Scott, R.N., and Ruby Nickson, R.N.; *Audie L. Murphy VA Hospital* (16)—Marc H. Weiner, M.D., Melissa Engle, C.R.T., C.C.R.C., and Paula Duran, M.D.; *New Jersey Medical School National TB Center-University of Medicine and Dentistry of New Jersey* (15)—Bonita T. Mangura, M.D., Lee B. Reichman, M.D., M.P.H., Maria Corazon Leus, R.N., Marilyn Owens, R.N., and Eileen Napolitano; *Division of TB Control, University of British Columbia* (12)—J. Mark FitzGerald, M.D., M.B., F.R.C.P. (I), F.R.C.P.C., Kevin Elwood, M.B., M.R.C.P.I., F.R.C.P.C., Kadria Alasaly, M.D., and Hossein Aliabadi M.D.; *Denver Public Health Department* (11)—Randall Reeves, M.D., William Burman, M.D., Jan Tapy, R.N., Lucy Arenas R.N., and Grace Sanchez; *Emory University Department of Medicine* (8)—Susan Ray, M.D., David P. Holland, M.D., Deidre Dixon, Gibson Barika, and Kanoa Folami; *University of California, San Francisco* (8)—Robert Jasmer, M.D., Charles Daley, M.D., Philip Hopewell, M.D., Puneet Dewan, M.D., Cindy Merrifield, R.N., Irinia Rudoy, M.D., Jill Israel, R.N., and Bill Stanton, R.N.; *University of Manitoba* (7)—Earl Hershfield, M.D., and Marian Roth, R.N.; *University of California, San Diego Medical Center* (6)—Antonino Catanzaro, M.D., Peach Francisco, R.N., and Judy Davis; *University of Southern California* (5)—Brenda E. Jones, M.D., Brian Wong M.D., Maria Brown M.P.H., and Bonnie P. Oamar, R.N.; *Vanderbilt University Medical Center* (4)—Timothy R. Sterling, M.D., and Linda Reeves-Hammock, R.N.; *Bellevue Hospital Center, New York University* (3)—Rany Condos, M.D., William Rom, M.D., M.P.H., and Laurie Sandman, R.N., M.P.H.; *Columbia University College of Physicians and Surgeons* (3)—Neil W. Schluger, M.D., Joseph Burzynski, M.D., M.P.H., Vilma Lozano, R.N., and Magda Wolk, R.N.; *Montreal Chest Institute* (3)—Richard J. Menzies, M.D., Kevin Schwartzman, M.D., M.P.H., Marthe Pelletier, and Chantal Valiquette; *Harlem Hospital Center* (3)—Wafaa El-Sadr, M.D., Mary Klein, R.N., and Yombo Tankoano; *Johns Hopkins University* (2)—Richard E. Chaisson, M.D., Susan Dorman, M.D., Gina Maltas, R.N., and Judith Hackman, R.N.; *Boston University Medical Center* (2)—John Bernardo, M.D., Jussi Saukkonen, M.D., C. Robert Horsburgh, Jr., M.D., Claire Murphy, R.N., M.S., N.P., and Denise Brett-Curran, R.N.; *Public Health-Seattle & King County* (1)—Masa Narita, M.D., and Debra Schwartz, R.N., M.N.; and *Washington DC VA Medical Center* (1)—Fred M. Gordin, M.D., Debra Benator, M.D., and Donna Sepulveda Conwell, R.N.

Data management and analysis were performed by Awal Khan, Ph.D., Lorna Bozeman, M.S., Anil Sharma, Erin Bliven, M.S., and Laura Podewils, Ph.D. Site monitoring was performed by Westat, represented by Bert Arevalo on the protocol team. Trial administration and data management were performed at the CDC by Sharlene Broadnax, Crystal Carter, Melissa Fagley, Lon Gross, Constance Henderson, Marie Hannett, Margaret Jackson, and Tashawnya Rainey. Microbiologic data collection was supervised by Lorna Bozeman, M.S. CDC laboratory testing was performed or supervised by Robert Cooksey, Ph.D., Jack Crawford, Ph.D., Lois Diem, Beverly Metchock, Dr. P.H., Glenn Morlock, David Sikes, Lauren Cowan, David Temporado, Sean Toney, and Adriane Niare. Data and safety monitoring were performed by Harold Jaffe, M.D., James Neaton, Ph.D., John Kaplan, M.D., and David Ashkin, M.D.

References

- Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1998;42:2066–2069.
- Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. *J Antimicrob Chemother* 1999;44:393–395.
- Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12–8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. *Antimicrob Agents Chemother* 1999;43:85–89.
- Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. *Am J Respir Crit Care Med* 2004;169:421–426.
- Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. *Antimicrob Agents Chemother* 2004;48:780–782.
- Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. *Am J Respir Crit Care Med* 2003;168:1342–1345.
- Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K, Jankus D, Debanne S, Charlebois E, Maciel E, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. *Int J Tuberc Lung Dis* (In press)
- Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh TD. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. *J Antimicrob Chemother* 2005;56:1169–1171.
- Mitchison D. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. *Am Rev Respir Dis* 1993;147:1062–1063.
- Tuberculosis Trials Consortium. Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons. *Lancet* 2002;360:528–534.
- Aber VR, Nunn AJ. Factors affecting relapse following short-course chemotherapy. *Bull Int Union Against Tuberc* 1978;53:260–264.
- Burman WJ, Johnson J, Goldberg S, Daley C, Munsiff S, Mosher A, Engle M, Choudhri S, Khan A, Chaisson R. Moxifloxacin vs. ethambutol in multidrug treatment of pulmonary tuberculosis: final results of a randomized double-blind trial. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 December 16–19. Washington, DC: American Society for Microbiology; 2005. p. 218.
- Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. *Am Rev Respir Dis* 1986;133:423–430.
- Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med* 2003;167:603–662.
- Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Public Health Service; 1985.
- Bozeman L, Burman W, Metchock B, Welch L, Weiner M. Fluoroquinolone susceptibility among *Mycobacterium tuberculosis* isolates from the United States and Canada. *Clin Infect Dis* 2005;40:386–391.
- East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. *Lancet* 1974;2:1100–1106.

18. East African/British Medical Research Council. Controlled trial of four short-course (6-month) regimens of chemotherapy for the treatment of pulmonary tuberculosis. *Lancet* 1974;2:1100-1106.
19. East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report. *Am Rev Respir Dis* 1978;118:39-48.
20. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. *Am Rev Respir Dis* 1978;118:219-227.
21. Tuberculosis Research Centre. Shortening short course chemotherapy: a randomized clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. *Indian J Tuberc* 2002;49:27-38.
22. El-Sadr W, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, Olibrice M, Medard F, Chirgwin KD, Mildvan D, et al. Evaluation of an intensive intermittent-induction regimen and short course duration of treatment for HIV-related pulmonary tuberculosis. *Clin Infect Dis* 1998;26:1148-1158.
23. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. *Chest* 1992;102:1815-1818.
24. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. *Am J Respir Crit Care Med* 2004;170:1131-1134.
25. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. *Chest* 2000;117:744-751.
26. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. *J Chemother* 2003;15:66-70.
27. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Antibiotic treatment of *Chlamydia pneumoniae* after acute coronary syndrome. *N Engl J Med* 2005;352:1646-1654.
28. Iannini PB, Kubin R, Reiter C, Tillotson G. Reassuring safety profile of moxifloxacin. *Clin Infect Dis* 2001;32:1112-1114.
29. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. *Pharmacotherapy* 2001;21:1468-1472.
30. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. *N Engl J Med* 2006;354:1352-1361.
31. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. *Am J Respir Crit Care Med* 2004;170:1124-1130.
32. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. *Antimicrob Agents Chemother* 1998;42:2060-2065.
33. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. *Tubercle* 1982;63:89-98.
34. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against *Mycobacterium tuberculosis* in mice. *Antimicrob Agents Chemother* 2001;45:3482-3486.
35. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. *Am J Respir Crit Care Med* 2006;174:94-101.